[Form 4] UNITEDHEALTH GROUP INC Insider Trading Activity
UnitedHealth Group (UNH) Form 4: This filing reports a non-derivative acquisition by Thomas E. Roos, Chief Accounting Officer, via an authorized filing on behalf of the reporting person. On 09/23/2025 the report shows an acquisition of 22.357 units recorded as dividend equivalents on outstanding restricted stock units, with a reported price of $0 because these are dividend-equivalent payments tied to RSUs and subject to the same vesting and forfeiture terms as the underlying awards. Following the transaction, the reporting person beneficially owned 29,593.519 shares, which includes shares acquired through UnitedHealth’s Employee Stock Purchase Plan. The filing was signed by an attorney-in-fact on 09/25/2025.
UnitedHealth Group (UNH) Form 4: Questa comunicazione riporta un'acquisizione non derivativa da parte di Thomas E. Roos, Chief Accounting Officer, effettuata tramite una presentazione autorizzata per conto della persona indicata nel rapporto. Il 23/09/2025 la relazione mostra un'acquisizione di 22.357 unità registrata come equivalenti di dividendo su azioni vincolate residue, con un prezzo riportato di $0 perché si tratta di pagamenti di dividendi legati agli RSU e soggetti agli stessi termini di vesting e perdita dei diritti come gli incentivi sottostanti. A seguito della transazione, la persona riportante possedeva 29,593.519 azioni, che includono azioni acquisite tramite il piano di acquisto di azioni dei dipendenti di UnitedHealth. La comunicazione è stata firmata da un procuratore ad acta in data 25/09/2025.
UnitedHealth Group (UNH) Formulario 4: Este archivo reporta una adquisición no derivada por Thomas E. Roos, Director de Contabilidad, realizada mediante una presentación autorizada en nombre de la persona reportante. El 23/09/2025 el informe muestra una adquisición de 22.357 unidades registradas como equivalentes de dividendo sobre las acciones restringidas en circulación, con un precio reportado de $0 porque se trata de pagos de dividendos vinculados a RSU y sujetos a los mismos términos de vesting y pérdida de derechos que los incentivos subyacentes. Tras la transacción, la persona reportante poseía 29,593.519 acciones, lo que incluye acciones adquiridas a través del Plan de Compras de Acciones para Empleados de UnitedHealth. La presentación fue firmada por un apoderado en virtud de poder el 25/09/2025.
UnitedHealth Group (UNH) Form 4: 이 제출은 보고자 진술인의 대리인을 통해 승인된 제출로 Thomas E. Roos, 최고 회계 책임자에 의한 비파생적 취득을 보고합니다. 2025년 9월 23일 보고서는 22.357 유닛의 취득을 배당금 등가물로 기록하고 있으며, 해당 RSU에 귀속되는 배당금 지급으로서 원가가 $0으로 보고되어 있습니다. 이는 기초 보상과 동일한 vesting 및 몰수 조건의 배당금 관련 지급임을 뜻합니다. 거래 후 보고자는 29,593.519주를 실질적으로 소유하게 되었으며, 여기에 UnitedHealth의 직원 주식매수계획을 통해 취득한 주식이 포함됩니다. 이 제출은 2025년 9월 25일에 대리인에 의해 서명되었습니다.
UnitedHealth Group (UNH) Formulaire 4 : Cette inscription rapporte une acquisition non dérivée par Thomas E. Roos, Chief Accounting Officer, effectuée via une présentation autorisée au nom de la personne déclarant. Le 23/09/2025, le rapport indique une acquisition de 22.357 unités enregistrées comme des équivalents de dividendes sur des actions restreintes en cours, avec un prix affiché de 0 $ car il s'agit de paiements de dividendes liés aux RSU et soumis aux mêmes conditions de vesting et de perte de droits que les incitations sous-jacentes. Suite à l'opération, la personne déclarant détenait 29 593.519 actions, ce qui inclut des actions acquises par le biais du plan d'achat d'actions pour les employés de UnitedHealth. Le dépôt a été signé par un mandataire en date du 25/09/2025.
UnitedHealth Group (UNH) Form 4: Diese Einreichung berichtet über eine nicht abgeleitete Erwerbung durch Thomas E. Roos, Chief Accounting Officer, erfolgt durch eine autorisierte Einreichung im Namen der meldenden Person. Am 23.09.2025 zeigt der Bericht einen Erwerb von 22,357 Einheiten, der als Dividendenvorteile auf ausstehende Restricted Stock Units verbucht wird, mit einem gemeldeten Preis von 0 $, da es sich um dividendenausgleichsbeiträge handelt, die denselben Vesting- und Verfallbedingungen wie die zugrunde liegenden Zusagen unterliegen. Nach der Transaktion besaß die meldende Person 29,593.519 Aktien, zu denen auch durch UnitedHealths Employee Stock Purchase Plan erworbene Aktien gehören. Die Einreichung wurde am 25.09.2025 von einem Bevollmächtigten unterzeichnet.
UnitedHealth Group (UNH) النموذج 4: يذكر هذا الإخطار اكتسابًا غير مشتق من قبل توماس إي. روز، كبير موظفي المحاسبة، من خلال تقديم مخول نيابة عن الشخص المبلِّغ. في 23/09/2025 يعرض التقرير استحواذًا على 22.357 وحدة مُسجَّلة كبدائل توزيعات على أسهم مقيدة قائمة، مع سعر مُبلغ عنه قدره $0 لأن هذه دفعات توزيعات مرتبطة بـ RSUs وتخضع لنفس شروط vesting وحرمان من الحقوق التي تنطبق على الجوائز الأساسية. عقب الصفقة، امتلك الشخص المبلِّغ فعليًا 29,593.519 سهمًا، وهو ما يشمل الأسهم المكتسبة من خلال خطة شراء أسهم الموظفين لدى UnitedHealth. وُقِّعت الإخطار من قبل وكيل قانوني في 25/09/2025.
UnitedHealth Group (UNH) 表格4： 本申报通过授权代表人对申报人办理的提交，报告了 Thomas E. Roos（首席会计官）的一项非衍生取得。2025年9月23日，报告显示以 22.357 单位的取得，记为对未行权受限股票单位的股息等价支付，报导的价格为 $0，因为这些是与 RSU 相关的股息等价支付，受与基础奖励相同的归属与没收条款约束。交易完成后，申报人实际拥有 29,593.519 股，其中包括通过 UnitedHealth 的员工股票购买计划获取的股份。该申报于 2025年9月25日 由一名代理签署。
- Non-cash compensation disclosed as dividend equivalents on RSUs, reflecting alignment of executive pay with shareholder returns
- Post-transaction beneficial ownership quantified at 29,593.519 shares, including Employee Stock Purchase Plan participation
- Timely filing with signature by attorney-in-fact dated 09/25/2025
- None.
Insights
TL;DR: Officer received dividend equivalents and increased reported beneficial ownership modestly; transaction is routine and non-cash.
The reported acquisition of 22.357 dividend-equivalent units reflects non-cash compensation tied to existing restricted stock units rather than an open-market purchase. Such dividend equivalents typically mirror stock dividends on unvested RSUs and are forfeitable if the underlying awards do not vest, so this does not represent an immediate transferable stake. The post-transaction beneficial ownership of 29,593.519 shares, which includes Employee Stock Purchase Plan shares, provides a snapshot of the reporting person’s stake but lacks context on total outstanding shares, so market-impact assessment is limited. Overall, this is a routine Section 16 disclosure with no material change in control or financing.
TL;DR: Governance-wise this is a standard insider-reporting event tied to compensation; no governance red flags disclosed.
The form indicates the reporting person is an officer (Chief Accounting Officer) and that the transaction relates to dividend equivalents on RSUs and ESPP participation. The filing is signed by an attorney-in-fact and includes the required explanatory remarks about forfeiture and ESPP inclusion. There are no indications of option exercises, sales, or related-party transactions. From a disclosure and compliance perspective, the form appears complete and routine for executive equity compensation reporting.
UnitedHealth Group (UNH) Form 4: Questa comunicazione riporta un'acquisizione non derivativa da parte di Thomas E. Roos, Chief Accounting Officer, effettuata tramite una presentazione autorizzata per conto della persona indicata nel rapporto. Il 23/09/2025 la relazione mostra un'acquisizione di 22.357 unità registrata come equivalenti di dividendo su azioni vincolate residue, con un prezzo riportato di $0 perché si tratta di pagamenti di dividendi legati agli RSU e soggetti agli stessi termini di vesting e perdita dei diritti come gli incentivi sottostanti. A seguito della transazione, la persona riportante possedeva 29,593.519 azioni, che includono azioni acquisite tramite il piano di acquisto di azioni dei dipendenti di UnitedHealth. La comunicazione è stata firmata da un procuratore ad acta in data 25/09/2025.
UnitedHealth Group (UNH) Formulario 4: Este archivo reporta una adquisición no derivada por Thomas E. Roos, Director de Contabilidad, realizada mediante una presentación autorizada en nombre de la persona reportante. El 23/09/2025 el informe muestra una adquisición de 22.357 unidades registradas como equivalentes de dividendo sobre las acciones restringidas en circulación, con un precio reportado de $0 porque se trata de pagos de dividendos vinculados a RSU y sujetos a los mismos términos de vesting y pérdida de derechos que los incentivos subyacentes. Tras la transacción, la persona reportante poseía 29,593.519 acciones, lo que incluye acciones adquiridas a través del Plan de Compras de Acciones para Empleados de UnitedHealth. La presentación fue firmada por un apoderado en virtud de poder el 25/09/2025.
UnitedHealth Group (UNH) Form 4: 이 제출은 보고자 진술인의 대리인을 통해 승인된 제출로 Thomas E. Roos, 최고 회계 책임자에 의한 비파생적 취득을 보고합니다. 2025년 9월 23일 보고서는 22.357 유닛의 취득을 배당금 등가물로 기록하고 있으며, 해당 RSU에 귀속되는 배당금 지급으로서 원가가 $0으로 보고되어 있습니다. 이는 기초 보상과 동일한 vesting 및 몰수 조건의 배당금 관련 지급임을 뜻합니다. 거래 후 보고자는 29,593.519주를 실질적으로 소유하게 되었으며, 여기에 UnitedHealth의 직원 주식매수계획을 통해 취득한 주식이 포함됩니다. 이 제출은 2025년 9월 25일에 대리인에 의해 서명되었습니다.
UnitedHealth Group (UNH) Formulaire 4 : Cette inscription rapporte une acquisition non dérivée par Thomas E. Roos, Chief Accounting Officer, effectuée via une présentation autorisée au nom de la personne déclarant. Le 23/09/2025, le rapport indique une acquisition de 22.357 unités enregistrées comme des équivalents de dividendes sur des actions restreintes en cours, avec un prix affiché de 0 $ car il s'agit de paiements de dividendes liés aux RSU et soumis aux mêmes conditions de vesting et de perte de droits que les incitations sous-jacentes. Suite à l'opération, la personne déclarant détenait 29 593.519 actions, ce qui inclut des actions acquises par le biais du plan d'achat d'actions pour les employés de UnitedHealth. Le dépôt a été signé par un mandataire en date du 25/09/2025.
UnitedHealth Group (UNH) Form 4: Diese Einreichung berichtet über eine nicht abgeleitete Erwerbung durch Thomas E. Roos, Chief Accounting Officer, erfolgt durch eine autorisierte Einreichung im Namen der meldenden Person. Am 23.09.2025 zeigt der Bericht einen Erwerb von 22,357 Einheiten, der als Dividendenvorteile auf ausstehende Restricted Stock Units verbucht wird, mit einem gemeldeten Preis von 0 $, da es sich um dividendenausgleichsbeiträge handelt, die denselben Vesting- und Verfallbedingungen wie die zugrunde liegenden Zusagen unterliegen. Nach der Transaktion besaß die meldende Person 29,593.519 Aktien, zu denen auch durch UnitedHealths Employee Stock Purchase Plan erworbene Aktien gehören. Die Einreichung wurde am 25.09.2025 von einem Bevollmächtigten unterzeichnet.
FAQ
What transaction does the UNH Form 4 filed for Thomas E. Roos report?
How many UnitedHealth (UNH) shares does the reporting person beneficially own after the transaction?
Do the dividend equivalents reported on the Form 4 immediately transfer to the reporting person?
Was the Form 4 filing properly signed and dated?
Does this Form 4 report any derivative transactions or open-market sales?
